Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Epidemiology
Erschienen in: European Journal of Epidemiology 7/2016

18.05.2016 | CORRESPONDENCE

The Syrian refugees crisis brings challenges to the health authorities in Europe: hepatitis A virus is a case in point

verfasst von: Nada Melhem, Khalil Kreidieh, Sami Ramia

Erschienen in: European Journal of Epidemiology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Excerpt

The ongoing 3-year Syrian Civil war has left hundreds of thousands killed or wounded in addition to the displacement of more than 6.5 million Syrians throughout the world [1]. According to the United Nations High Commission on Refugees (UNHCR), the bulk of those displaced are hosted by neighboring countries: Lebanon (approximately 1.2 million people), Jordan (approximately 650,000), Iraq (approximately 250,000) and Turkey (approximately 1.9 million) [1]. It has been reported that slightly more than 10 % of the displaced Syrian refugees are seeking safety in Europe. The majority of the Syrian refugees in Europe are concentrated in Serbia and Germany (57 %) compared to 31 % in Sweden, Hungary, Austria, Netherlands and Bulgaria, and 12 % in the remaining 37 European Countries [2]. These numbers are increasing daily along with the associated challenge of their adequate settlement [3]. …
Literatur
1.
2.
3.
The Lancet. Adapting to migration as a planetary force. Lancet (Lond, Engl). 2015;386(9998):1013.
4.
Alawieh A, Musharrafieh U, Jaber A, Berry A, Ghosn N, Bizri AR. Revisiting leishmaniasis in the time of war: the Syrian conflict and the Lebanese outbreak. Int J Infect Dis. 2014;29:115–9.CrossRefPubMed
5.
Cookson ST, Abaza H, Clarke KR, Burton A, Sabrah NA, Rumman KA, et al. Impact of and response to increased tuberculosis prevalence among Syrian refugees compared with Jordanian tuberculosis prevalence: case study of a tuberculosis public health strategy. Conflict Health. 2015;9:18.CrossRefPubMedPubMedCentral
6.
Ritz N, Brinkmann F, Garcia BS, Tebruegge M, Kampmann B. Tuberculosis in young refugees. Lancet (Lond, Engl). 2015;386(10012):2475–6.CrossRef
7.
8.
Tajaldin B, Almilaji K, Langton P, Sparrow A. Defining polio: closing the gap in global surveillance. Ann Global Health. 2015;81(3):386–95.CrossRef
9.
Djebbi A, Bahri O, Mokhtariazad T, Alkhatib M, Ben Yahia A, Rezig D, et al. Identification of measles virus genotypes from recent outbreaks in countries from the Eastern Mediterranean Region. J Clin Virol. 2005;34(1):1–6.CrossRefPubMed
10.
Cousins S. Syrian crisis: health experts say more can be done. Lancet (Lond, Engl). 2015;385(9972):931–4.CrossRef
11.
Matheny SC, Kingery JE. Hepatitis A. Am Family Phys. 2012;86(11):1027–34 quiz 10–2.
12.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653–7.CrossRefPubMed
13.
Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine. 2000;18(Suppl 1):S71–4.CrossRefPubMed
14.
15.
16.
Jacobsen KH, Koopman JS. The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol. 2005;34(3):600–9.CrossRefPubMed
17.
Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. Morb Morta Wkly Rep. 2009;58(3):1–27.
18.
Luyten J, Beutels P. Costing infectious disease outbreaks for economic evaluation: a review for hepatitis A. PharmacoEconomics. 2009;27(5):379–89.CrossRefPubMed
19.
20.
Arie S. Polio outbreak leads to calls for a “vaccination ceasefire” in Syria. BMJ (Clin res ed). 2013;347:f6682.
21.
22.
Eichner M, Brockmann SO. Polio emergence in Syria and Israel endangers Europe. Lancet (Lond, Engl). 2013;382(9907):1777.CrossRef
23.
Hives-Wood S. Syrian refugees could bring polio to Europe, experts warn. BMJ (Clin res ed). 2013;347:f6778.
24.
25.
26.
Melhem NM, Talhouk R, Rachidi H, Ramia S. Hepatitis A virus in the Middle East and North Africa region: a new challenge. J Viral Hepat. 2014;21(9):605–15.CrossRefPubMed
27.
Kohl I, Nemecek V, Summerova M, Chlibek R, Nad’ova K, Minarikova O. Long-term protective effect of post-exposure Havrix administration during viral hepatitis Type A outbreaks. Eur J Epidemiol. 2006;21(12):893–9.CrossRefPubMed
28.
Lopez EL, Contrini MM, Mistchenko A, Debbag R. Long-term immunity after two doses of inactivated hepatitis A vaccine, in Argentinean children. Pediatr Infect Dis J. 2010;29(6):568–70.PubMed
29.
Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines. 2005;4(4):459–71.CrossRefPubMed
30.
Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine. 2012;31(1):3–11.CrossRefPubMed
31.
Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J Med Virol. 2011;83(11):1885–91.CrossRefPubMed
32.
World Health Organization. WHO position paper on hepatitis A vaccines: june 2012-recommendations. Vaccine. 2013;31(2):285–6.CrossRef
33.
34.
Mellou K, Sideroglou T, Papaevangelou V, Katsiaflaka A, Bitsolas N, Verykouki E, et al. Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks. PLoS ONE. 2015;10(1):e0116939.CrossRefPubMedPubMedCentral
35.
36.
37.
Gossner CM, Severi E, Danielsson N, Hutin Y, Coulombier D. Changing hepatitis A epidemiology in the European Union: new challenges and opportunities. Eur Surveill. 2015;20(16):21101.CrossRef
38.
Severi E, Tavoschi L, Carillo Santisteve P, Bonfigli S, Westrell T, Arnheim Dahlstrom L, et al. Hepatitis A incidence in the EU: what can we learn from the available data? J Viral Hepat. 2015;22(S2):1–18.
39.
Rein DB, Hicks KA, Wirth KE, Billah K, Finelli L, Fiore AE, et al. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States. Pediatrics. 2007;119(1):e12–21.CrossRefPubMed
40.
World Health Organization. Hepatitis A vaccines. Wkly Epidemiol Rec. 2000;75(5):38–44.
41.
Semenza JC, Carrillo-Santisteve P, Zeller H, Sandgren A, van der Werf MJ, Severi E, et al. Public health needs of migrants, refugees and asylum seekers in Europe, 2015: infectious disease aspects. Eur J Public Health. 2016;26:ckw023.CrossRef
Metadaten
Titel
The Syrian refugees crisis brings challenges to the health authorities in Europe: hepatitis A virus is a case in point
verfasst von
Nada Melhem
Khalil Kreidieh
Sami Ramia
Publikationsdatum
18.05.2016
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 7/2016
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-016-0163-5

Weitere Artikel der Ausgabe 7/2016

European Journal of Epidemiology 7/2016 Zur Ausgabe

LETTER TO THE EDITOR

Morbidity of asylum seekers in a medium-sized German city

MORTALITY

All-cause and cause-specific mortality of different migrant populations in Europe

SOCIAL EPIDEMIOLOGY

Differences in mortality by immigrant status in Italy. Results of the Italian Network of Longitudinal Metropolitan Studies

CARDIOVASCULAR DISEASE

Cardiovascular disease incidence and survival: Are migrants always worse off?

COMMENTARY

Society and health of migrants

META-ANALYSIS

Tobacco smoking and the risk of gallbladder disease